Abstract：
:Current prophylactic measures have greatly reduced recurrence rates of hepatitis B after liver transplantation. HBIG remains a critically important compound and although there is variability in dosing regimens and target anti-HBs levels, it is the backbone of recurrence prevention. Adjuvant therapies with nucleoside/nucleotide analogs alone have been limited by drug-resistant strains of HBV, but the armamentarium of these molecules continues to grow and hence the management of the post-LT HBV patient will evolve further. Currently lamivudine with HBIG remains an excellent option provided the patient has not developed resistance, especially in the pre-LT period. Adefovir is the drug of choice in that setting and perhaps the preferred drug in the pre-LT setting to allow the use of lamivudine post-LT. Further testing with tenofovir and newer compounds in development will expand these options. The use of multiple nucleoside analogs is an intriguing option, based on the HIV experience of reducing drug resistance and optimizing viral suppression, and will likely be further studied.
journal_name
Clin Liver Disjournal_title
Clinics in liver diseaseauthors
Poordad FFdoi
10.1016/j.cld.2004.02.011subject
Has Abstractpub_date
2004-05-01 00:00:00pages
461-73issue
2eissn
1089-3261issn
1557-8224pii
S1089-3261(04)00022-4journal_volume
8pub_type
杂志文章,评审abstract：:With obesity reaching epidemic proportions in the United States, it is imperative that hepatologists have an understanding of the medical ramifications and methods of treatment. Evaluation of nonalcoholic fatty liver disease may get the patient into the office,but weight reduction may provide a therapeutic hurdle. Thi...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2004.04.003
更新日期：2004-08-01 00:00:00
abstract：:The global risk of hepatocellular carcinoma (HCC) has been largely driven by hepatitis B virus (HBV) infection for the past century, along with hepatitis C virus (HCV), aflatoxin, excessive alcohol consumption, and obesity/diabetes. The dominant effect of HBV on global HCC risk should decline as the population vaccina...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2011.03.006
更新日期：2011-05-01 00:00:00
abstract：:Pharmacologic management of hepatic encephalopathy includes a broad range of therapies. This article covers the specific mainstays of therapies, such as antimicrobials and laxatives, with an established evidence base. This article also covers newer modalities of therapies, such as fecal microbiota transplant, probioti...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2020.01.005
更新日期：2020-05-01 00:00:00
abstract：:Hepatic granulomas are a common finding in systemic sarcoidosis, but most patients remain asymptomatic. Elevated alkaline phosphatase is the most common sign of hepatic sarcoidosis (HS). Lacking a specific diagnostic test, the diagnosis of HS is one of exclusion. Therapy may be indicated in a minority of patients to c...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2018.12.012
更新日期：2019-05-01 00:00:00
abstract：:Renal dysfunction is a frequent complication in patients with endstage liver disease awaiting orthotopic liver transplantation. Although the stereotypical form of renal dysfunction is the hepatorenal syndrome, common causes of acute kidney injury include prerenal azotemia and acute tubular necrosis in this population....
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2011.08.001
更新日期：2011-11-01 00:00:00
abstract：:There have been major advances in the field of hepatitis B (HBV) over the last few decades. These advances have resulted in the understanding of the natural history of chronic HBV infection, effective vaccines against the virus, sensitive assays for screening and monitoring of treatment, and effective treatments for v...
journal_title：Clinics in liver disease
pub_type： 历史文章,杂志文章,评审
doi：10.1016/j.cld.2010.05.003
更新日期：2010-08-01 00:00:00
abstract：:A variety of benign and malignant neoplasms can be encountered in the liver. Hematoxylin and eosin-stained tissue sections alone may not yield sufficient information to definitively diagnose liver tumors; therefore, ancillary studies with immunohistochemical markers can play a crucial role in differentiating the diffe...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2010.10.001
更新日期：2010-11-01 00:00:00
abstract：:Hepatic encephalopathy (HE) represents a continuum of transient and reversible neurologic and psychiatric dysfunction. It is a reversible state of impaired cognitive function or altered consciousness in patients with liver disease or portosystemic shunting. Over the last several years, high-quality studies have been c...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2012.03.009
更新日期：2012-05-01 00:00:00
abstract：:Mathematical modeling of hepatitis C viral kinetics has been an important tool in understanding hepatitis C virus (HCV) infection dynamics and in estimating crucial in vivo parameters characterizing the effectiveness of HCV therapy. Because of the introduction of direct-acting antiviral agents, there is a need to exte...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2012.09.003
更新日期：2013-02-01 00:00:00
abstract：:Osteopenia, in the form of osteoporosis, is a common complication of chronic cholestatic liver diseases and, although its cause is poorly understood, it appears to be intimately related to the cholestasis itself. With more patients surviving longer with successful liver transplantation, the clinical significance of su...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70015-5
更新日期：1998-05-01 00:00:00
abstract：:Recurrent autoimmune hepatitis (AIH) and de novo AIH are 2 important causes of late graft failure after liver transplantation (LT). Recurrent AIH occurs in patients who undergo LT for AIH. De novo AIH occurs in patients who are transplanted for etiologies other than AIH. Although typically treated with standard treatm...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2016.12.010
更新日期：2017-05-01 00:00:00
abstract：:Xenotransplantation of the liver, in its broadest conception, might involve the transplantation of an intact organ or xenogeneic hepatocytes, or the use of an intact xenogeneic liver or cells as an ex vivo "device." The indications for xenotransplantation include not only hepatic failure but also, potentially, the tre...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70135-5
更新日期：2000-08-01 00:00:00
abstract：:Drug-induced liver injury (DILI) can be predictable or idiosyncratic and has an estimated incidence of approximately 20 cases per 100,000 persons per year. DILI is a common cause of acute liver failure in the United States. No accurate tests for diagnosing DILI exist, and its diagnosis is based on exclusion of other c...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2016.08.012
更新日期：2017-02-01 00:00:00
abstract：:Histologic cholestasis and clinical jaundice may be seen in all stages of alcoholic liver disease. In rare cases, isolated cholestasis without significant steatosis, hepatitis, or cirrhosis is identified in an alcoholic patient. The mechanisms of ethanol-induced cholestasis are not well studied but may involve compres...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70086-6
更新日期：1999-08-01 00:00:00
abstract：:Primary biliary cirrhosis is an insidious disease that progresses through the clinical phases: preclinical, asymptomatic, symptomatic, and liver insufficiency. The outlook of patients diagnosed with PBC has improved significantly over the past 2 decades because more patients are being diagnosed earlier in the disease ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2008.02.012
更新日期：2008-05-01 00:00:00
abstract：:Good management of patients at risk for the development of hepatocellular carcinoma includes regular ultrasound surveillance, and aggressive management of lesions detected at ultrasound. Good radiology and good pathology are essential to the appropriate management of these small lesions. With good quality testing it i...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2007.08.011
更新日期：2007-11-01 00:00:00
abstract：:Liver cancer is the second leading cause of global cancer mortality. The major risk factors for hepatocellular carcinoma (HCC) are being addressed with success by prevention efforts. Vaccination against hepatitis B virus has reduced incidence of HCC in Taiwan and is partly responsible for lower rates in China. New inf...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2015.01.001
更新日期：2015-05-01 00:00:00
abstract：:Epidemiologic studies suggest that 10% to 15% of patients infected with hepatitis C virus (HCV) are coinfected with hepatitis B virus (HBV) in the United States as a result of the shared modality of transmission, but the true prevalence is not known. The progression of liver disease to cirrhosis and hepatocellular car...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2019.04.003
更新日期：2019-08-01 00:00:00
abstract：:Nonsteroidal anti-inflammatory drugs are among the most common drugs associated with drug-induced liver injury, with an estimated incidence of between 3 and 23 per 100,000 patient years. Nimesulide, sulindac, and diclofenac seem to be associated with the highest risk and the only risk factor consistently identified is...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2007.06.004
更新日期：2007-08-01 00:00:00
abstract：:Cirrhosis is a complex process in which the architecture of the liver is replaced by structurally abnormal nodules due to cirrhosis. Cirrhosis frequently leads to the development of portal hypertension. In children, portal hypertension may be caused by a wide range of etiologies, including extrahepatic portal vein obs...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2018.06.007
更新日期：2018-11-01 00:00:00
abstract：:The most consistently identified predictive factors for a response to both IFN-alpha monotherapy and IFN-alpha in combination with ribavirin are a low HCV RNA level, the absence of fibrosis, infection with HCV genotype 2 and 3, and a prolonged duration of treatment. In addition, an early response to IFN-alpha predicts...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70238-5
更新日期：1999-11-01 00:00:00
abstract：:Bile acid synthetic defects are uncommon disorders that cause progressive cholestatic liver disease that is often lethal in infancy or early childhood. Five specific primary defects have been described. Diagnosis is based on mass spectrometry of urine and serum. Pathogenesis of liver injury is related to persistent re...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70144-6
更新日期：2000-11-01 00:00:00
abstract：:Early diagnosis of HCC is possible because certain risk factors for this tumor are known and because sensitive and relatively inexpensive diagnostic tools are available. Early diagnosis of HCC is also possible because of the long phase of asymptomatic tumor growth and the tumor's tendency to grow as a solitary mass in...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70156-2
更新日期：2001-02-01 00:00:00
abstract：:The diagnosis of hepatic encephalopathy is predominantly clinical, and the tests available assist in the diagnosis only by excluding other causes. Covert hepatic encephalopathy, which is defined as abnormal performance on psychometric tests when standard neurologic examination is completely normal, has gained widespre...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2015.04.001
更新日期：2015-08-01 00:00:00
abstract：:Primary liver cancer is the fifth most common malignancy worldwide and the third leading cause of cancer mortality. Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the United States encompassing a spectrum of entities marked by hepatic steatosis in the absence of significant alco...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2009.07.007
更新日期：2009-11-01 00:00:00
abstract：:Although recent evidence indicates that the quasispecies nature of HCV constitutes a critical strategy for the virus to survive in the host, the mechanisms of viral persistence remain unknown. Similarly, the correlates of immune protection in a limited proportion of individuals who succeed in clearing HCV are still la...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70200-2
更新日期：2001-11-01 00:00:00
abstract：:Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) carries an increased risk for development of advanced liver disease. Lifestyle modifications with diet and exercise have been the initial management reco...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2017.06.010
更新日期：2017-11-01 00:00:00
abstract：:Development of ethanol-induced fatty liver, alcoholic hepatitis, and cirrhosis has been attributed in part to nutritional deficiencies for many years. Special attention must be focused on treating alcohol-induced liver disease while providing replacement of deficient amino acids, vitamins, minerals, and other nutrient...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2004.11.003
更新日期：2005-02-01 00:00:00
abstract：:In the past two decades, pediatric liver transplantation has become the state-of-the-art operation with anticipated success and limited mortality. The future success of pediatric liver transplantation will require thoughtful solutions to the delicate balance of risk to donors and recipients, the complex needs of the a...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2005.10.004
更新日期：2006-02-01 00:00:00
abstract：:The Model for End-stage Liver Disease (MELD) has been demonstrated to be an excellent predictor of survival in patients who have end-stage liver disease. It is derived from the international normalized ratio (INR) of prothrombin time, serum creatinine, and serum total bilirubin. The major use of the MELD score is to p...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2008.09.001
更新日期：2009-02-01 00:00:00
